🇺🇸 FDA
Patent

US 9249227

Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

granted A61KA61K2039/505A61K39/3955

Quick answer

US patent 9249227 (Use of semaphorin-4D binding molecules for treating neurodegenerative disorders) held by VACCINEX, INC. expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
VACCINEX, INC.
Grant date
Tue Feb 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K2039/505, A61K39/3955, A61K45/06, A61P